Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...
Jasmine McCabe-Gossett began noticing mild neuropathy in her hands and feet. It quickly progressed to “one of the most ...
Chronic inflammatory demyelinating polyneuropathy (CIPD) can have a substantial impact on patients everyday life and, ...
Lucia Notterpek, Ph.D., professor and senior associate dean for research at the University of Nevada, Reno School of Medicine ...
Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with ...
Zacks Investment Research on MSN8d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite SuccessImmunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback